Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3056506
Reference Type
Journal Article
Subtype
Letter
Title
Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA
Author(s)
Nordenbo, AM; Somnier, FE
Year
1992
Is Peer Reviewed?
1
Journal
The Lancet
ISSN:
0140-6736
EISSN:
1474-547X
Report Number
IPA/93/1021042
Volume
340
Issue
8828
Page Numbers
1168
Language
English
PMID
1359250
Abstract
IPA COPYRIGHT: ASHP Acute deterioration of myasthenia gravis after a single intravenous administration of 0.2 ml/kg of gadopentetate dimeglumine (Magnevist) is reported in a 59-yr-old man who had magnetic resonance imaging of the brain with gadopentetate dimeglumine as contrast medium. The patient immediately had general weakness of skeletal muscles, including difficulties in walking and raising both arms. During the following month the condition rapidly deteriorated with development of features characteristic of myasthenia gravis. The neuromuscular disease was treated with pyridostigmine, prednisone, and plasma exchanges, resulting in rapid improvement.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity